Sorafenib

For research use only.

Catalog No.S7397 Synonyms: BAY 43-9006

246 publications

Sorafenib Chemical Structure

Molecular Weight(MW): 464.82

Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.

Size Price Stock Quantity  
RMB 1205.41 In stock
RMB 2214.52 In stock
RMB 5503.41 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Sorafenib has been cited by 246 publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Targets
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
In vitro

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NELFZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[1e5dKSzVyPUCuNFAxODB|MEOg{txO NUHY[mlXW0GQR1XS
MONO-MAC-6 MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHzTWM2OD1yLkCwOFE5KM7:TR?= MX7TRW5ITVJ?
ALL-PO NGPEVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwMEOxPFQh|ryP MoKyV2FPT0WU
NKM-1 NFvhS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwMEe0NVYh|ryP M4fZNnNCVkeHUh?=
CGTH-W-1 M2q1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDDO49zUUN3ME2wMlI2ODJ{IN88US=> M1zD[XNCVkeHUh?=
BB65-RCC NHP3bHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrwTWM2OD1yLkS3NFc{KM7:TR?= NIW3SZpUSU6JRWK=
NOS-1 NVvPOZlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULBNVhTUUN3ME2wMlU3OzZizszN MorOV2FPT0WU
SH-4 NFznd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fkS2lEPTB;MD62OVYyOyEQvF2= NH\O[nZUSU6JRWK=
HOP-62 MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLE[4ZKSzVyPUCuPFUxQDhizszN MVfTRW5ITVJ?
HCC2998 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\sfWlEPTB;MD64PFgyQCEQvF2= M3XjWHNCVkeHUh?=
GDM-1 NX7BepBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[4TWM2OD1yLkmwOlk5KM7:TR?= M3nTbnNCVkeHUh?=
KM12 NH;rR25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PRO2lEPTB;MT6wNlA6QCEQvF2= NHPkd3hUSU6JRWK=
LB2518-MEL NEHtVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;xTlBKSzVyPUGuNlA5ODlizszN MUPTRW5ITVJ?
NCI-H1436 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFwMkG2O|gh|ryP M2fzTHNCVkeHUh?=
EM-2 NH:yd|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFwM{W1O|gh|ryP Mn7SV2FPT0WU
LAMA-84 NIrFOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zZTmlEPTB;MT6zO|Y1QCEQvF2= MXPTRW5ITVJ?
KG-1 NHi3UVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFwNEe5N|Uh|ryP M1G4XXNCVkeHUh?=
A388 NFLpVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDnTWM2OD1zLkW5NVY2KM7:TR?= M2rKe3NCVkeHUh?=
no-10 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwNkG3NlYh|ryP NG[0[FdUSU6JRWK=
SF126 NFPNWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTnTWM2OD1zLk[zPFEzKM7:TR?= NFLJc|dUSU6JRWK=
MEG-01 Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPJTWM2OD1zLkiwPVgh|ryP Mn3PV2FPT0WU
A3-KAW NITUVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFwOEi0NkDPxE1? NFXZVXZUSU6JRWK=
D-247MG MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\mcopKSzVyPUKuNVQ1QCEQvF2= NWm0SmxyW0GQR1XS
OVCAR-4 NH:4TXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXsbHR{UUN3ME2yMlIyOzl|IN88US=> MkSxV2FPT0WU
NCI-SNU-1 NEHrTYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;wUmlEPTB;Mj6zNVYzKM7:TR?= MkDVV2FPT0WU
NCI-H2171 M3qxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEflbFRKSzVyPUKuN|k4PjRizszN M{i0[HNCVkeHUh?=
SIG-M5 NWf2UIMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVyxZodMUUN3ME2yMlQzOjR{IN88US=> NY\2XotIW0GQR1XS
BE-13 MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLjR4plUUN3ME2yMlY6PjB7IN88US=> M{\1S3NCVkeHUh?=
K052 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLNTWM2OD1{Lke0OlE3KM7:TR?= NY[2OVM4W0GQR1XS
L-540 NIDSOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJwN{W3PFkh|ryP MWHTRW5ITVJ?
KMOE-2 NHzhbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJwOEGzOUDPxE1? MXHTRW5ITVJ?
MFH-ino MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHryVY1KSzVyPUKuPVIyQDVizszN NHXPU5VUSU6JRWK=
HL-60 MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrrTWM2OD1|LkC2Nlk6KM7:TR?= NFXaVnNUSU6JRWK=
HCC2218 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHsTWM2OD1|LkGyNFA{KM7:TR?= MUfTRW5ITVJ?
TE-5 NWrneWRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3FbmpRUUN3ME2zMlE{OTZ{IN88US=> M4HQ[HNCVkeHUh?=
MZ1-PC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\qSWlEPTB;Mz60O|UxQSEQvF2= MmLmV2FPT0WU
MRK-nu-1 MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDtV2N6UUN3ME2zMlYyPDZ6IN88US=> M3KzTXNCVkeHUh?=
MZ7-mel MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrCPZlKSzVyPUOuOlYxQTlizszN MVfTRW5ITVJ?
BC-1 NEPCbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV2yZ5g5UUN3ME2zMlc1ODJizszN NVrTcVJIW0GQR1XS
ST486 MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zwRWlEPTB;Mz64N|Y4OyEQvF2= MkDQV2FPT0WU
KS-1 NH3kT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnKTWM2OD1|Lki4NVk5KM7:TR?= NGXlSWtUSU6JRWK=
SK-NEP-1 NUfHcZFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTRwMU[4NVUh|ryP NYGydWtjW0GQR1XS
BC-3 NHq5Uo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTRwMkOzPVEh|ryP MXLTRW5ITVJ?
NCI-H1581 NUDkZpVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrvOll2UUN3ME20MlI5Pzl6IN88US=> MVjTRW5ITVJ?
MHH-PREB-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTRwNEC0PFQh|ryP NVnF[GFHW0GQR1XS
NOMO-1 M3vVW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofyTWM2OD12LkS4PVA2KM7:TR?= M{TSTXNCVkeHUh?=
QIMR-WIL MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmf5TWM2OD13LkC3Nlk1KM7:TR?= M33tNXNCVkeHUh?=
SF539 MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLGb4xKSzVyPUWuNVMzOjdizszN M{P3fnNCVkeHUh?=
TE-12 NEHRVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;E[WJDUUN3ME21MlI1QTJ7IN88US=> NFvaR4ZUSU6JRWK=
NCI-H510A MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L4WWlEPTB;NT60NVY5PSEQvF2= NG\yOotUSU6JRWK=
JAR NYniTnE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj5UmZKSzVyPUWuOVA5OjRizszN MlzGV2FPT0WU
no-11 M3;QcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEGx[2ZKSzVyPUWuO|M2PjhizszN M2HrfXNCVkeHUh?=
BV-173 M{m2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrGNnhNUUN3ME21Mlk2Pjh{IN88US=> NFnJXHdUSU6JRWK=
SR NWr1THlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;BeIlKSzVyPU[uNFA3PzhizszN NEGzXVZUSU6JRWK=
MOLT-16 NFjwZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rVN2lEPTB;Nj6yOVI3PiEQvF2= NGewUmdUSU6JRWK=
MZ2-MEL NHzSR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnNelhqUUN3ME22MlMyQDN7IN88US=> M2PFdHNCVkeHUh?=
SW954 M1XXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLnfHRKSzVyPU[uOFU5PjZizszN MWTTRW5ITVJ?
ML-2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHXblNHUUN3ME22MlUzQDR7IN88US=> M1:zRXNCVkeHUh?=
OCI-AML2 MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTQTWM2OD14Lk[xNFYzKM7:TR?= Mk\mV2FPT0WU
SIMA MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XtWmlEPTB;Nz6wNFExOSEQvF2= NF6wSllUSU6JRWK=
DOHH-2 MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[xb|RKSzVyPUeuNFU3PzZizszN NVL4WYlWW0GQR1XS
697 MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2n1bWlEPTB;Nz6wOVk5QSEQvF2= NWfuUVhIW0GQR1XS
NB1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL1TXJKSzVyPUeuOFA1ODdizszN Ml\sV2FPT0WU
D-392MG NI\D[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;VeWJWUUN3ME23MlYzPjZ|IN88US=> MoflV2FPT0WU
ES8 NFXhVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFe0e5ZKSzVyPUeuO|Y2ODNizszN NWHQOWtDW0GQR1XS
RPMI-8226 NFfMbmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DFW2lEPTB;Nz64OFUyOSEQvF2= MXPTRW5ITVJ?
IST-MEL1 M4nmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjVb|JKSzVyPUiuOFAxODJizszN MWrTRW5ITVJ?
NB14 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDrTWM2OD16Lk[zNVM{KM7:TR?= M4r2U3NCVkeHUh?=
HD-MY-Z MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlq1TWM2OD16Lk[zO|Q3KM7:TR?= MVfTRW5ITVJ?
TE-10 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHm3WHZKSzVyPUiuO|Y{PTNizszN NH3wdHRUSU6JRWK=
LC-1F MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS0cII{UUN3ME25MlExQDN2IN88US=> NE\XUYFUSU6JRWK=
OS-RC-2 MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLTTWM2OD17LkGxNlQ{KM7:TR?= NGC1coJUSU6JRWK=
NCI-SNU-16 NGHaTlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3OzS2lEPTB;OT6yNVAzPiEQvF2= MXrTRW5ITVJ?
SHP-77 M2HGN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULJ[llKUUN3ME25MlcyPjZ{IN88US=> M2LGNnNCVkeHUh?=
A4-Fuk MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TxWWlEPTB;OT63OVYyKM7:TR?= MlqyV2FPT0WU
NB6 M1zifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHnco1KSzVyPUmuO|YxOjlizszN Ml7HV2FPT0WU
JiyoyeP-2003 NIi3PXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWewUVNqUUN3ME2xNE41PzR3IN88US=> Mo[yV2FPT0WU
DMS-114 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn6dIJFUUN3ME2xNE42PDRzIN88US=> NYfnTndxW0GQR1XS
NB7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmCwTWM2OD1zMD63OVI3KM7:TR?= MXzTRW5ITVJ?
NCI-H747 NI\lbIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX5TWM2OD1zMT6xNlE3KM7:TR?= M1[0SXNCVkeHUh?=
HH M3G4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PVSGlEPTB;MUGuN|g4PiEQvF2= MXPTRW5ITVJ?
EW-18 NYDWNJhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfRd4pKSzVyPUGxMlkxPDRizszN MX7TRW5ITVJ?
CHP-126 NXT0V3I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTMblE3UUN3ME2xNU46PzN6IN88US=> NITaSVZUSU6JRWK=
NTERA-S-cl-D1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH2wN3ZKSzVyPUGyMlAzPzhizszN NI\wdVhUSU6JRWK=
DEL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF{LkC5PFUh|ryP MoCxV2FPT0WU
LU-139 NXnOOYtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXTW5QxUUN3ME2xNk42PDF|IN88US=> MVPTRW5ITVJ?
P30-OHK NHXyempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvxPFlKSzVyPUGyMlU1PzlizszN M2Loe3NCVkeHUh?=
NCI-H1522 M2T6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF{Lke0OkDPxE1? M1H4WnNCVkeHUh?=
NCI-H1299 MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF|LkK5NVEh|ryP M2DwZXNCVkeHUh?=
UACC-257 NUO5fHl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:3OVVUUUN3ME2xN{42OTJ4IN88US=> MX7TRW5ITVJ?
Calu-6 M4rZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nSfGlEPTB;MUOuOlA1PiEQvF2= M4TVTHNCVkeHUh?=
NCI-H1882 NIPOfnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rWTGlEPTB;MUOuPFU2PSEQvF2= Mom5V2FPT0WU
BB30-HNC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF2LkC2NFkh|ryP NXvLTG97W0GQR1XS
ES1 MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ro[mlEPTB;MUSuNVU2OSEQvF2= MlrQV2FPT0WU
NCI-H1694 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG4TWM2OD1zND60PFEyKM7:TR?= MYHTRW5ITVJ?
IST-SL1 NGDQSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHFUnFuUUN3ME2xOE46PjF4IN88US=> MX\TRW5ITVJ?
ECC4 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoKyTWM2OD1zNT6wOVU5KM7:TR?= Mlr3V2FPT0WU
MDA-MB-134-VI MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnEfZIzUUN3ME2xOU41OTNzIN88US=> M176T3NCVkeHUh?=
SCH MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTNTWM2OD1zNT60O|I5KM7:TR?= NITmSVhUSU6JRWK=
SK-N-FI NE\0RmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTtSFdKSzVyPUG1MlY2OzRizszN NV3XepFIW0GQR1XS
HDLM-2 M2G3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TROmlEPTB;MU[uNFcyPCEQvF2= NXm4do04W0GQR1XS
Ramos-2G6-4C10 NWTrVlVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmmzTWM2OD1zNj6xNlk4KM7:TR?= MX7TRW5ITVJ?
EW-24 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF4LkG2OlEh|ryP MVXTRW5ITVJ?
NCI-H2141 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHCTWM2OD1zNj6xPFkh|ryP Mm\lV2FPT0WU
LC4-1 NX3nO2hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLGTWM2OD1zNj62NVE6KM7:TR?= NXv3dno6W0GQR1XS
HT-144 NHzmUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWW2OVRnUUN3ME2xO{4xODZizszN NHHSZoJUSU6JRWK=
SK-MEL-1 M37Tcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\qTWM2OD1zNz6wNFczKM7:TR?= MWDTRW5ITVJ?
SCC-15 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF5LkG2N|gh|ryP NV7UXZY1W0GQR1XS
C8166 Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi2XWlKSzVyPUG3MlY5OzNizszN Mn74V2FPT0WU
GOTO MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:1TWM2OD1zNz64N|Q1KM7:TR?= NGnRWJBUSU6JRWK=
COR-L279 NVG3WlMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrpSXpkUUN3ME2xPE4yOzZ{IN88US=> Mlv6V2FPT0WU
K-562 M3fK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nKVmlEPTB;MUiuO|E1OyEQvF2= M{LSR3NCVkeHUh?=
ES3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfuOnBKSzVyPUG4MlgxPDFizszN M3myU3NCVkeHUh?=
LU-165 MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF7LkewNFgh|ryP M{LHbHNCVkeHUh?=
KM-H2 NXTSdWdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvzbI1KSzVyPUKwMlMyQDRizszN Mo\MV2FPT0WU
RL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjud2NmUUN3ME2yNE46Pjl{IN88US=> MU\TRW5ITVJ?
EW-3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDqeXZKSzVyPUKxMlE5QDlizszN NYDjSIVIW0GQR1XS
A101D MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\ZUWlEPTB;MkGuN|c2OiEQvF2= NF7rUHlUSU6JRWK=
HUTU-80 M1GxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\0XIRoUUN3ME2yNU4{QTR4IN88US=> MnzNV2FPT0WU
NCI-H23 MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe3PXZKSzVyPUKxMlM6QTJizszN MUnTRW5ITVJ?
PF-382 NVrT[5NUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1viSWlEPTB;MkGuOFQxOyEQvF2= MnzjV2FPT0WU
LB373-MEL-D NEW2SohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3sTWM2OD1{MT61OlE2KM7:TR?= NELVXoJUSU6JRWK=
TE-8 NHLOc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjXfFBOUUN3ME2yNU43Ozl2IN88US=> NIHZZ|hUSU6JRWK=
TE-9 M3vYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj6R3lKSzVyPUKxMlg2OTNizszN NEXDOG9USU6JRWK=
Daudi NEHUOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fJWmlEPTB;MkGuPVMxPCEQvF2= M4rLTHNCVkeHUh?=
D-542MG MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnuzTWM2OD1{Mj6wNlU3KM7:TR?= MmLxV2FPT0WU
U-698-M NWrQWFhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP2U4tKSzVyPUKyMlQ3ODNizszN MkTWV2FPT0WU
ES6 NWLSSZo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqyTWM2OD1{Mj63N|Y3KM7:TR?= NGWyR4ZUSU6JRWK=
DU-4475 NW\yTGN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJ|Lki4PVch|ryP MkTiV2FPT0WU
ECC12 NVPDWINJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnPdJFkUUN3ME2yOE4zQDB|IN88US=> NYrYNW5vW0GQR1XS
C2BBe1 MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlj3TWM2OD1{ND6zNlM6KM7:TR?= NVvS[W93W0GQR1XS
IST-SL2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe1OHhqUUN3ME2yOE41OzZ{IN88US=> MUjTRW5ITVJ?
DJM-1 M4\mcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml36TWM2OD1{ND61NlIyKM7:TR?= NEHpU3FUSU6JRWK=
DMS-153 MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEG3UopKSzVyPUK0Mlg3OTRizszN NVSwdWw2W0GQR1XS
NB13 M{OzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmroTWM2OD1{NT6wNlY2KM7:TR?= M13GUHNCVkeHUh?=
SK-N-DZ MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJ4LkO0NVQh|ryP NVnkWmh2W0GQR1XS
COR-L88 NULlVZE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJ4LkW3PVYh|ryP MoHyV2FPT0WU
LU-65 MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTVNnV5UUN3ME2yOk45PTN3IN88US=> NG\VcJdUSU6JRWK=
TGBC1TKB NHTM[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrFUopkUUN3ME2yOk46QDJ6IN88US=> NXvHcXBlW0GQR1XS
THP-1 NWT4c4cyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXJbW1wUUN3ME2yO{4zOTRzIN88US=> MkjSV2FPT0WU
ONS-76 Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XicWlEPTB;MkeuN|MzKM7:TR?= MXzTRW5ITVJ?
LC-2-ad NVfze5J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkflTWM2OD1{Nz62NlMyKM7:TR?= MWjTRW5ITVJ?
EW-13 M1q3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zjcGlEPTB;MkmuNVc1PiEQvF2= MVzTRW5ITVJ?
MS-1 NFm1S3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4C0V2lEPTB;M{CuO|I4QCEQvF2= MUnTRW5ITVJ?
NCI-H2227 NYT4Zmh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDNTWM2OD1|MD65PFA3KM7:TR?= NFficXhUSU6JRWK=
LXF-289 NFTXOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTNzLkS0PVIh|ryP NFjSSI1USU6JRWK=
MC116 MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPLS3VKSzVyPUOyMlA5OjZizszN MlX5V2FPT0WU
EVSA-T NYnuPJhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPSe3RKSzVyPUOyMlI2QDVizszN NVzkS2V5W0GQR1XS
CTB-1 NWHhSnF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LmNmlEPTB;M{OuNVExOSEQvF2= MlH2V2FPT0WU
COLO-320-HSR Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTN|LkG2NFMh|ryP M2PWNXNCVkeHUh?=
NCI-H2196 Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq3TWM2OD1|Mz6yOVU4KM7:TR?= M1vLR3NCVkeHUh?=
LB2241-RCC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTN|LkOxN|Uh|ryP NYWyXlV[W0GQR1XS
LS-513 MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTN|Lki2N|gh|ryP Mk\aV2FPT0WU
LP-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j1[GlEPTB;M{OuPVk2PiEQvF2= MVrTRW5ITVJ?
A253 Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTN2LkKyPVYh|ryP NX;HZ3FqW0GQR1XS
SK-MM-2 M3jDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWW3T29oUUN3ME2zOE46PDVzIN88US=> MV;TRW5ITVJ?
NCI-H1963 NEPWfJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXs[2VtUUN3ME2zOU4{ODd{IN88US=> NYjsWIg1W0GQR1XS
MMAC-SF NXGz[5VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYGyTpVQUUN3ME2zOU45Pzh3IN88US=> M4nXVHNCVkeHUh?=
LB831-BLC MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PGemlEPTB;M{[uNFY2PCEQvF2= MlTYV2FPT0WU
WSU-NHL NFPtVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPkU29KSzVyPUO2MlE3PCEQvF2= Ml[1V2FPT0WU
CESS NW\W[GlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PlUWlEPTB;M{[uNlg1QCEQvF2= MXzTRW5ITVJ?
NEC8 NWHBOIc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\oZ2lEPTB;M{[uOVg{PSEQvF2= NF32Z4pUSU6JRWK=
KNS-42 NYe4UnNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom4TWM2OD1|Nz6xNlM4KM7:TR?= MWXTRW5ITVJ?
MHH-CALL-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTN5LkG4NlEh|ryP MoL3V2FPT0WU
K5 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV73S2JyUUN3ME2zPE41OyEQvF2= MXXTRW5ITVJ?
CP66-MEL NX\UcGE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTN7LkC3N|Mh|ryP Mni3V2FPT0WU
OPM-2 M2PLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDQTWM2OD1|OT64OFMzKM7:TR?= NEftNXFUSU6JRWK=
IST-MES1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTRyLkOwPVYh|ryP Mo\4V2FPT0WU
EC-GI-10 NHfjTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH5dnFFUUN3ME20NU42QDB3IN88US=> NH7jOpNUSU6JRWK=
CTV-1 NIThS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\n[ZlKSzVyPUSyMlg1ODZizszN MX3TRW5ITVJ?
DG-75 M3;VSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3INnBKSzVyPUSzMlc2QTVizszN M3nrenNCVkeHUh?=
KNS-81-FD MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7DWIdKSzVyPUS1MlQxPThizszN MXzTRW5ITVJ?
NCI-H82 MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3BVohKSzVyPUS1MlU4PThizszN MnLsV2FPT0WU
RPMI-8866 NInWZ|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonHTWM2OD12Nj6xPFc{KM7:TR?= MX\TRW5ITVJ?
ACN MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nNPGlEPTB;NE[uOFM1KM7:TR?= NYmzd5hJW0GQR1XS
NCI-H1395 MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFO4doJKSzVyPUS2MlQ4PTZizszN MULTRW5ITVJ?
NCI-H209 MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T3UmlEPTB;NEeuNVQxPSEQvF2= MVXTRW5ITVJ?
TGW NFjPZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LBNWlEPTB;NEmuNFc6OSEQvF2= M3jscXNCVkeHUh?=
NCI-H748 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXZTWM2OD12OT60O|U{KM7:TR?= M1uycnNCVkeHUh?=
EKVX NILMTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPhZ4c{UUN3ME20PU43PjJ6IN88US=> MWjTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LC3-I / LC-3II / ATG5; 

PubMed: 23392173     


Sorafenib induces the conversion of LC3 in a dose-dependent manner. PLC5, Hep3B, SK-Hep1 and HepG2 were exposed to sorafenib at the indicated doses for 16 h and the expression levels of LC3-II were analyzed by western blot.

p-STAT3 / STAT3 / Mcl-1; 

PubMed: 23392173     


Effects of sorafenib on STAT3-related proteins in HCC cells. The cells were treated with sorafenib at the indicated dose for 16 h. 

β-catenin / Survivin / Mcl-1 / PTMA; 

PubMed: 26517516     


Co-inhibition of β-catenin and PTMA by sorafenib in HCC cells. Cell lines indicated on top were treated or not with 10 μM sorafenib for 24 hrs and processed for immuno-blotting. IC50 values (the concentration of sorafenib that inhibits 50% of cell growth) for each cell line are indicated below the panels.

pERK / ERK; 

PubMed: 22286758     


Western blot analysis of p-ERK (T202/Y204) and ERK at indicated time points in HCT116 cells treated with 20 μmol/L sorafenib.

p-PKM2(y105) / PMK2 / Caspase-9; 

PubMed: 26959741     


Sorafenib downregulates the p-PKM2 (Y105) at the indicated doses after treatment for 24 h.

RET(pY1016) / VEGFR2(pY1214) / MEK1(pT292) / ERK(pY204); 

PubMed: 22941289     


Sorafenib affected the phosphorylation of receptor tyrosine kinase RET and VEGFR2, as well as MEK/ERK kinases signaling cascades in three cell lines. Three cell lines were treated by sorafenib with two concentration gradients, 1 and 5 μmol/L/L, and then collected after 2, 4, and 8 h, cells without sorafenib treatment were as the controls (0 h). Total proteins were extracted and quantified to be used in Western blot assays. (A) Sorafenib inhibited RET and VEGFR2 phosphorylation dose-dependently while activated MEK and ERK phosphorylation in A549 cells. (B) Sorafenib also inhibited RET and VEGFR2 phosphorylation, and slightly activated MEK and ERK phosphorylation in HeLa cells. (C) Sorafenib activated the phosphorylation of RET, VEGFR2, and MEK, but inhibited ERK phosphorylation in HepG2 cells.

Cyclin D1; 

PubMed: 26039995     


Dose-escalation effects of sorafenib or SC-1 for 24 h on STAT3-related proteins in HSC-T6 and LX2 cells.

23392173 26517516 22286758 26959741 22941289 26039995
Growth inhibition assay
Cell viability; 

PubMed: 26039995     


Dose-escalation and time-dependent effects of sorafenib for 24 or 48 h on cell viability in HSC-T6, LX2, and mouse primary HSCs. Circles, mean; bars, SE (n = 3).

26039995
Immunofluorescence
p65; 

PubMed: 22286758     


HCT116 cells were treated with 20 μmol/L sorafenib or 10 ng/mL TNF-α for 3 hours then fixed. Immunofluorescence was carried out as described in the Materials and Methods for p65 (green) and DAPI (blue). Representative pictures (400×) are shown.

cytochrome c; 

PubMed: 22278289     


Immunoflourescent staining and quantification of mitochondrial membrane potential (appearing in red, mitotracker) and cytochrome c (appearing in green, FITC) in 22Rv1 and PC3 treated with 20 μM sorafenib for 24 h.

22286758 22278289
ELISA
TGF-beta / CD206; 

PubMed: 26158762     


In Macrophage, TGF-β secretion and CD206 were confirmed by ELISA.

Caspase-9 / Caspase-3; 

PubMed: 30923462     


Caspase-9 and caspase-3 activities were measured via ELISA assay. FCCP, an activator of mitophagy, was added into the medium of sorafenib-treated cells to activate mitophagy. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. *p < 0.05 vs. control group; #p < 0.05 vs. Sorafenib + Ad-cont group; #p < 0.05 vs. Sorafenib + Ad-LATS2 group.

26158762 30923462
In vivo Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

Protocol

Kinase Assay:

[1]

- Collapse

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
Cell Research:

[1]

- Collapse
  • Cell lines: MDA-MB-231, and HAoSMC
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • Dosages: ~60 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL warmed (135.53 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+45%PEG400+50%H2O
For best results, use promptly after mixing.
0.375mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 464.82
Formula

C21H16ClF3N4O3

CAS No. 284461-73-0
Storage powder
in solvent
Synonyms BAY 43-9006
Smiles CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04000737 Recruiting Drug: YIV-906+Sorafenib|Drug: Placebo+Sorafenib Advanced Hepatocellular Carcinoma Yiviva Inc. January 10 2020 Phase 2
NCT03958669 Recruiting -- Hepatocellular Carcinoma|Sorafenib University Hospital Tuebingen|German Federal Ministry of Education and Research November 1 2019 --
NCT03764293 Recruiting Drug: SHR-1210|Drug: Apatinib|Drug: Sorafenib Locally Advanced or Metastatic and Unresectable HCC Jiangsu HengRui Medicine Co. Ltd. June 10 2019 Phase 3
NCT03582618 Recruiting Drug: Sorafenib|Drug: CVM-1118 Hepatocellular Carcinoma|Advanced Cancer TaiRx Inc. July 12 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Related Raf Products

Tags: buy Sorafenib | Sorafenib supplier | purchase Sorafenib | Sorafenib cost | Sorafenib manufacturer | order Sorafenib | Sorafenib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID